1 - 25 of 57 results for author:"Buechler C." in Literature citations
Results Customize
› Repeat search in UniProtKB (12)
| Chemerin induces CCL2 and TLR4 in synovial fibroblasts of patients with rheumatoid arthritis and osteoarthritis. Eisinger K., Bauer S., Schaffler A., Walter R., Neumann E., Buechler C., Muller-Ladner U., Frommer K.W. Exp. Mol. Pathol. 92:90-96(2012) · Mapped (4) |
| Admission levels of soluble CD137 are increased in patients with acute pancreatitis and are associated with subsequent complications. Shao Z., Schaffler A., Hamer O., Dickopf J., Goetz A., Landfried K., Voelk M., Kopp A., Herfarth H., Karrasch T. et al. Exp. Mol. Pathol. 92:1-6(2012) · Mapped (2) |
| Adiponectin reduces connective tissue growth factor in human hepatocytes which is already induced in non-fibrotic non-alcoholic steatohepatitis. Walter R., Wanninger J., Bauer S., Eisinger K., Neumeier M., Weiss T.S., Amann T., Hellerbrand C., Schaffler A., Scholmerich J. et al. Exp. Mol. Pathol. 91:740-744(2011) · Mapped (6) |
| Adiponectin stimulates release of CCL2, -3, -4 and -5 while the surface abundance of CCR2 and -5 is simultaneously reduced in primary human monocytes. Neumeier M., Bauer S., Bruhl H., Eisinger K., Kopp A., Abke S., Walter R., Schaffler A., Buechler C. Cytokine 56:573-580(2011) · Mapped (40) |
| Soluble CD163 is not increased in visceral fat and steatotic liver and is even suppressed by free fatty acids in vitro. Bauer S., Weiss T.S., Wiest R., Schacherer D., Hellerbrand C., Farkas S., Scherer M.N., Ritter M., Schmitz G., Schaffler A. et al. Exp. Mol. Pathol. 91:733-739(2011) · Mapped (3) |
| Systemic resistin is increased in type 2 diabetic patients treated with loop diuretics. Bauer S., Neumeier M., Wanninger J., Walter R., Kopp A., Bala M., Schaffler A., Buechler C. J. Diabetes Complicat. 25:377-381(2011) · Mapped (2) |
| MMP-9 activity is increased by adiponectin in primary human hepatocytes but even negatively correlates with serum adiponectin in a rodent model of non-alcoholic steatohepatitis. Wanninger J., Walter R., Bauer S., Eisinger K., Schaffler A., Dorn C., Weiss T.S., Hellerbrand C., Buechler C. Exp. Mol. Pathol. 91:603-607(2011) · Mapped (12) |
| Systemic and hepatic vein galectin-3 are increased in patients with alcoholic liver cirrhosis and negatively correlate with liver function. Wanninger J., Weigert J., Wiest R., Bauer S., Karrasch T., Farkas S., Scherer M.N., Walter R., Weiss T.S., Hellerbrand C. et al. Cytokine 55:435-440(2011) · Mapped (9) |
| In vivo suppression of visfatin by oral glucose uptake: evidence for a novel incretin-like effect by glucagon-like peptide-1 (GLP-1). Bala M., Martin J., Kopp A., Hanses F., Buechler C., Schaffler A. J. Clin. Endocrinol. Metab. 96:2493-2501(2011) · Mapped (1) |
| Adiponectin induces the transforming growth factor decoy receptor BAMBI in human hepatocytes. Wanninger J., Neumeier M., Bauer S., Weiss T.S., Eisinger K., Walter R., Dorn C., Hellerbrand C., Schaffler A., Buechler C. FEBS Lett. 585:1338-1344(2011) · Mapped (4) |
| Portal levels of latent transforming growth factor-beta are related to liver function in patients with liver cirrhosis. Wanninger J., Wiest R., Bauer S., Neumeier M., Eisinger K., Farkas S., Scherer M.N., Schaffler A., Buechler C. Eur J Gastroenterol Hepatol 23:218-223(2011) · Mapped (9) |
| Sterol regulatory element-binding protein 2 (SREBP2) activation after excess triglyceride storage induces chemerin in hypertrophic adipocytes. Bauer S., Wanninger J., Schmidhofer S., Weigert J., Neumeier M., Dorn C., Hellerbrand C., Zimara N., Schaffler A., Aslanidis C. et al. Endocrinology 152:26-35(2011) · Mapped (2) |
| Adiponectin receptor binding proteins--recent advances in elucidating adiponectin signalling pathways. Buechler C., Wanninger J., Neumeier M. FEBS Lett. 584:4280-4286(2010) · Mapped (4) |
| C1q/TNF-related protein-3 represents a novel and endogenous lipopolysaccharide antagonist of the adipose tissue. Kopp A., Bala M., Buechler C., Falk W., Gross P., Neumeier M., Scholmerich J., Schaffler A. Endocrinology 151:5267-5278(2010) · Mapped (2) |
| Impaired hepatic removal of interleukin-6 in patients with liver cirrhosis. Wiest R., Weigert J., Wanninger J., Neumeier M., Bauer S., Schmidhofer S., Farkas S., Scherer M.N., Schaffler A., Scholmerich J. et al. Cytokine 53:178-183(2011) · Mapped (5) |
| Low-abundant adiponectin receptors in visceral adipose tissue of humans and rats are further reduced in diabetic animals. Bauer S., Weigert J., Neumeier M., Wanninger J., Schaffler A., Luchner A., Schnitzbauer A.A., Aslanidis C., Buechler C. Arch. Med. Res. 41:75-82(2010) · Mapped (6) |
| Serum galectin-3 is elevated in obesity and negatively correlates with glycosylated hemoglobin in type 2 diabetes. Weigert J., Neumeier M., Wanninger J., Bauer S., Farkas S., Scherer M.N., Schnitzbauer A., Schaffler A., Aslanidis C., Scholmerich J. et al. J. Clin. Endocrinol. Metab. 95:1404-1411(2010) · Mapped (9) |
| Adiponectin downregulates galectin-3 whose cellular form is elevated whereas its soluble form is reduced in type 2 diabetic monocytes. Weber M., Sporrer D., Weigert J., Wanninger J., Neumeier M., Wurm S., Stogbauer F., Kopp A., Bala M., Schaffler A. et al. FEBS Lett. 583:3718-3724(2009) · Mapped (9) |
| Circulating levels of chemerin and adiponectin are higher in ulcerative colitis and chemerin is elevated in Crohn's disease. Weigert J., Obermeier F., Neumeier M., Wanninger J., Filarsky M., Bauer S., Aslanidis C., Rogler G., Ott C., Schaffler A. et al. Inflamm. Bowel Dis. 16:630-637(2010) · Mapped (4) |
| Adiponectin-stimulated CXCL8 release in primary human hepatocytes is regulated by ERK1/ERK2, p38 MAPK, NF-kappaB, and STAT3 signaling pathways. Wanninger J., Neumeier M., Weigert J., Bauer S., Weiss T.S., Schaffler A., Krempl C., Bleyl C., Aslanidis C., Scholmerich J. et al. Am. J. Physiol. Gastrointest. Liver Physiol. 297:G611-8(2009) · Mapped (26) |
| Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes. Weigert J., Neumeier M., Wanninger J., Filarsky M., Bauer S., Wiest R., Farkas S., Scherer M.N., Schaffler A., Aslanidis C. et al. Clin. Endocrinol. (Oxf) 72:342-348(2010) · Mapped (1) |
| Adiponectin upregulates monocytic activin A but systemic levels are not altered in obesity or type 2 diabetes. Weigert J., Neumeier M., Wanninger J., Schober F., Sporrer D., Weber M., Schramm A., Wurm S., Stogbauer F., Filarsky M. et al. Cytokine 45:86-91(2009) · Mapped (5) |
| Elevated adiponectin serum levels in patients with chronic alcohol abuse rapidly decline during alcohol withdrawal. Buechler C., Schaffler A., Johann M., Neumeier M., Kohl P., Weiss T., Wodarz N., Kiefer P., Hellerbrand C. J. Gastroenterol. Hepatol. 24:558-563(2009) · Mapped (3) |
| Insulin induces monocytic CXCL8 secretion by the mitogenic signalling pathway. Wurm S., Neumeier M., Weigert J., Wanninger J., Gerl M., Gindner A., Schaffler A., Aslanidis C., Scholmerich J., Buechler C. Cytokine 44:185-190(2008) · Mapped (1) |
| Serum levels of adiponectin are associated with diabetic retinopathy and with adiponectin gene mutations in Caucasian patients with diabetes mellitus type 2. Zietz B., Buechler C., Kobuch K., Neumeier M., Scholmerich J., Schaffler A. Exp. Clin. Endocrinol. Diabetes 116:532-536(2008) · Mapped (3) |